5 results about "Thromboembolic disorder" patented technology

The present invention provides compounds useful for the treatment or prevention of diseases or conditions involving (a) thromboembolic disorders, (b) inflammatory disorders, or (c) plasma kallikrein activity. [Solution] A compound of formula (I), or its tautomers, stereoisomers, isotope substitutions, or pharmaceutically acceptable salts or solvates is provided. TIFF2026062690000101.tif47128

The invention relates to the technical field of medicines, and finds that a natural product amentoflavone can be used as a GPR35 (G-protein coupled receptor 35, GPR35) receptor agonist and application thereof, the compound is amentoflavone, has GPR35 receptor agonist activity, is a GPR35 receptor agonist, can be used for treating thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction, and can be used for treating various diseases such as thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction. Therefore, a novel GPR35 receptor stimulant seedling compound with a clear action target can be provided for the related diseases.

The application discloses a drug-loaded system and a preparation method and application thereof, and belongs to the technical field of medicines. The drug-loaded system is a drug system in which a nano drug-loaded material is carried on a supermolecular engineering modified frozen platelet; the nano drug-loaded material is a drug-loaded nanomaterial modified by a first modifier; the supermolecular engineering modified frozen platelet is a liquid nitrogen quick-frozen activated platelet modified by a second modifier; and the first and second modifiers can be self-assembled and combined. The frozen platelet retains thrombus targeting, and after the supermolecular system is engineered to carry the nano drug system, the targeted delivery and rapid release of drugs to a thrombus site can be realized, the drug-loaded system has high safety and specificity, and therefore has high broad-spectrum and promotion values. The preparation method of the drug-loaded system is simple, and the drug-loaded system can be used for preparing a medicine for treating thromboembolic diseases.

This disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, and which are therefore useful for the treatment of diseases treatable by BTK inhibition, such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Pharmaceutical compositions containing these compounds and processes for their preparation are also provided.